TVRD

Tvardi Therapeutics Inc

0.8300

Nov 03 • 10:28 AM ET +0.0247 (3.07%)

Healthcare Biotechnology USA Nano NASD

Peers: PALI PLRX ABVX CNTB ACRS ALMS MCRB SYRE TPST CLRB

Index	-
Market Cap	11.07M
Enterprise Value	-4.56M
Income	-26.06M
Sales	0.00M
Book/sh	0.89
Cash/sh	1.18
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Jan 31, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.93
P/C	0.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.87
Current Ratio	1.87
Debt/Eq	0.02
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.78
EPS next Y	-2.18
EPS next Q	-0.57
EPS this Y	31.66%
EPS next Y	1.96%
EPS next 5Y	1.03%
EPS past 3/5Y	61.55% -
Sales past 3/5Y	- -
EPS Y/Y TTM	82.57%
Sales Y/Y TTM	-100.00%
EPS Q/Q	31.47%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	2.04% -

Insider Own	24.71%
Insider Trans	0.00%
Inst Own	16.83%
Inst Trans	-12.27%
ROA	-85.08%
ROE	-126.19%
ROIC	-310.13%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-13.41%
SMA50	-38.00%
SMA200	-69.51%
Trades

Shs Outstand	13.34M
Shs Float	10.04M
Short Float	3.74%
Short Ratio	2.04
Short Interest	0.38M
52W High	5.69 -85.41%
52W Low	0.77 7.39%
Volatility	10.80% 8.94%
ATR (14)	0.10
RSI (14)	31.22
Beta	0.33
Rel Volume	0.05
Avg Volume	184.64K
Volume	1,700

Perf Week	-4.08%
Perf Month	-27.19%
Perf Quarter	-58.50%
Perf Half Y	-77.51%
Perf YTD	-80.70%
Perf Year	-81.60%
Perf 3Y	-98.29%
Perf 5Y	-99.87%
Perf 10Y	-99.61%
Recom	1.78
Target Price	9.62
Prev Close	0.81
Price	0.83
Change %	3.07%

Consensus

Buy

Avg. Price Target

$9.62

Implied Upside

+1,059.0%

Analysts12incl. previous ratings

Rating Distribution6 Buy · 4 Hold · 2 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 20, 2026	Initiated	CChardan Capital Markets	Buy	$8	+863.9%
Jul 08, 2026	Upgrade	RRaymond James	Mkt Perform → Outperform	$10	+1,104.8%
Jul 08, 2026	Upgrade	PPiper Sandler	Neutral → Overweight	$13	+1,466.3%
Jun 08, 2026	Initiated	HH.C. Wainwright	Buy	$9	+984.3%
Apr 20, 2026	Downgrade	BBarclays	Equal Weight → Underweight	$3	+261.4%
Oct 14, 2025	Downgrade	RRaymond James	Outperform → Mkt Perform
Oct 14, 2025	Downgrade	BBarclays	Overweight → Equal Weight	$5	+502.4%
Oct 13, 2025	Initiated	BBarclays	Overweight	$61	+7,249.4%
Oct 13, 2025	Downgrade	PPiper Sandler	Overweight → Neutral	$78 → $4	+381.9%
Oct 13, 2025	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Jul 14, 2025	Initiated	RRaymond James	Outperform	$62	+7,369.9%
Jul 11, 2025	Initiated	CCantor Fitzgerald	Overweight	$52	+6,165.1%
Jun 12, 2025	Initiated	PPiper Sandler	Overweight	$78	+9,297.6%
May 21, 2025	Initiated	OOppenheimer	Outperform	$65	+7,731.3%
May 15, 2025	Initiated	BBTIG Research	Buy	$55	+6,526.5%
Jun 13, 2024	Downgrade	SStifel	Buy → Hold	$6 → $1	+20.5%
Jun 13, 2024	Downgrade	NNeedham	Buy → Hold
Jun 13, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral
Jun 13, 2024	Downgrade	CCanaccord Genuity	Buy → Hold	$10 → $1	+20.5%
Mar 08, 2023	Downgrade	BBofA Securities	Neutral → Underperform	$13 → $6	+622.9%

Oct-14-26 08:00AM	Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference (GlobeNewswire)
Sep-24-26 08:00AM	New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC) (GlobeNewswire) -19.70%
Aug-26-26 08:00AM	Tvardi Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
Aug-14-26 07:07AM	Tvardi: Q2 Earnings Snapshot (Associated Press) +7.34%
07:00AM	Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Aug-12-26 08:00AM	Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 (GlobeNewswire)
Jul-30-26 07:30AM	Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 (GlobeNewswire)
Jul-07-26 07:00AM	Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement (GlobeNewswire) +54.23%
May-21-26 08:00AM	Tvardi Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire) -6.75%
May-08-26 07:11AM	Tvardi: Q1 Earnings Snapshot (Associated Press)
07:00AM	Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update (GlobeNewswire)
Apr-02-26 08:00AM	Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium (GlobeNewswire)
Mar-31-26 04:22PM	Tvardi: Q4 Earnings Snapshot (Associated Press) -5.66%
04:01PM	Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update (GlobeNewswire)
Feb-12-26 08:00AM	Tvardi Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Jan-08-26 04:05PM	Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.74% +7.57%
08:00AM	Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights (GlobeNewswire)
Nov-18-25 09:55AM	Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
08:00AM	Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (Business Wire)
Nov-13-25 04:08PM	Tvardi: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update (Business Wire)
Nov-04-25 08:00AM	Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (Business Wire)
Oct-28-25 09:55AM	Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Oct-24-25 08:51AM	Lost Money on Tvardi Therapeutics, Inc. (TVRD)? Contact Levi & Korsinsky to Protect Your Rights (Newsfile)
Oct-16-25 09:35AM	Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround (Zacks)
Oct-14-25 11:24AM	TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals (Zacks)
07:53AM	AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance (BioPharma Dive)
Oct-13-25 07:30AM	Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis (Business Wire) -83.92%
Aug-21-25 08:00AM	Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference (Business Wire)
Aug-14-25 06:17PM	Tvardi: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update (Business Wire)
Jul-18-25 07:30AM	This Strong Buy Stock Could Be the Next Big Biotech Breakout (Barchart)
Jul-15-25 08:00AM	Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference (Business Wire) -12.47%
Jun-01-25 06:05AM	Oppenheimer Predicts Up to ~550% Jump for These 2 Strong Buy Stocks (TipRanks)
May-27-25 08:00AM	Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis (Business Wire) +14.78%
May-20-25 08:00AM	Tvardi Therapeutics to Participate in Upcoming Investor Conferences (Business Wire) +5.88%
May-13-25 04:05PM	Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update (Business Wire)
May-06-25 07:00AM	Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference (Business Wire) -5.54%
Apr-14-25 11:50AM	Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics (GlobeNewswire) +13.26%
Dec-27-24 07:00AM	Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split (GlobeNewswire) -15.98%
Dec-18-24 07:00AM	Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement (GlobeNewswire)
06:45AM	Tessera gets sickle cell funding; Corvus shares slide on eczema data (BioPharma Dive)
Nov-14-24 07:31PM	Cara: Q3 Earnings Snapshot (Associated Press Finance) -5.04%
Aug-15-24 01:55PM	Cara: Q2 Earnings Snapshot (Associated Press Finance)
Jul-11-24 07:00AM	Cara Therapeutics Announces Exploration of Strategic Alternatives (GlobeNewswire) +27.97%
Jun-13-24 09:51AM	Chipotle, McDonald's initiated: Wall Street's top analyst calls (The Fly) -34.72%
Jun-12-24 04:01PM	Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica (GlobeNewswire)
May-13-24 08:55PM	CARA Stock Earnings: Cara Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:07PM	Cara: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Cara Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 07:00AM	Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
Apr-02-24 07:00AM	Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-07-24 07:00AM	Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024 (GlobeNewswire) +6.05%
06:40AM	7 F-Rated Stocks to Sell in March 2024 (InvestorPlace)
Mar-05-24 09:07AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.98%
07:51AM	Q4 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-04-24 08:51PM	CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +5.24%
05:10PM	Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Cara: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-12-24 04:01PM	Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 (GlobeNewswire) -8.54%
Jan-22-24 10:19AM	Cara Layoffs 2024: What to Know About the Latest CARA Job Cuts (InvestorPlace)
07:00AM	Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026 (GlobeNewswire)
Dec-18-23 07:00AM	Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis (GlobeNewswire) -48.85%
Nov-14-23 11:04AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.20%
08:48AM	Q3 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-23 06:00PM	Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) +12.38%
04:15PM	Cara: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Cara Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-09-23 11:38AM	These Biotech Stocks Could Double Your Money, According To Analysts (Benzinga) -6.72%
Nov-06-23 10:00AM	Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline (Zacks)
Nov-02-23 07:00AM	Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty (GlobeNewswire)
Oct-23-23 07:00AM	Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023 (GlobeNewswire)
Sep-25-23 07:00AM	Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients (GlobeNewswire)
Sep-05-23 07:00AM	Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -10.00%
Aug-10-23 02:53AM	Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-08-23 05:54AM	Q2 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 05:15PM	Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.75%
04:09PM	Cara: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Cara Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 07:00AM	Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors (GlobeNewswire)
Aug-02-23 07:00AM	Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-24-23 07:00AM	Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023 (GlobeNewswire)
Jun-14-23 01:37PM	The past five years for Cara Therapeutics (NASDAQ:CARA) investors has not been profitable (Simply Wall St.)
Jun-13-23 06:30AM	3 Small-Cap Stocks to Sell in June Before They Crash and Burn (InvestorPlace)
Jun-02-23 06:46PM	Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Jun-01-23 07:00AM	Cara Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 06:34PM	7 Stocks With 1,000% Upside Potential (InvestorPlace) -7.56%
May-25-23 06:40AM	Cara Therapeutics, Inc.'s (NASDAQ:CARA) P/S Is On The Mark (Simply Wall St.) -6.55%
May-18-23 04:53PM	Hero or Zero? 7 Speculative Small-Cap Stocks to Make You Rich or Broke. (InvestorPlace) -8.22%
02:00AM	Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus (PR Newswire)
May-16-23 11:02AM	Q1 2023 Cara Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +7.23%
May-15-23 05:15PM	Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Cara: Q1 Earnings Snapshot (AP Finance)
04:01PM	Cara Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 09:38AM	Cara Therapeutics, Inc. (NASDAQ:CARA) is a favorite amongst institutional investors who own 65% (Simply Wall St.)
May-01-23 07:00AM	Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023 (GlobeNewswire)
Apr-26-23 08:00PM	CARA: What does Argus have to say about CARA? (Argus Research)
Apr-10-23 07:00AM	Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)

Show Previous News

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX.

CEO & DirectorDr. Imran Alibhai Ph.D.

M.B.A.Mr. Dan Conn J.D.

Chief Medical OfficerDr. John Kauh M.D.

Co-Founder & Scientific Advisory Board MemberMr. David J. Tweardy M.D.

Co-Founder & Chairman of Scientific Advisory BoardDr. Ronald A. DePinho M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVRD

Tvardi Therapeutics Inc

Upgrade your Finviz experience